MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.17224

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2022

Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.

Avni-Biron Irit, Mishael Tali, Zittan Eran, Livne-Margolin Moran, Zinger Adar, Tzadok Roie, Goldenberg Rosie, Kopylov Uri, Ron Yulia, Hadar Eran, Helman Sarit, Granovsky Sorina Grisaru, Ollech Jacob E, Arazi Ayelet, Farkash Rivka, Pauker Maor H, Yanai Henit, Dotan Iris, Shitrit Ariella Bar-Gil

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Women with inflammatory bowel diseases (IBD) often receive biologics to maintain remission during pregnancy.

AIMS: To assess maternal and neonatal outcomes in patients with IBD treated with ustekinumab (UST) during pregnancy

METHODS

In a multicentre, prospective cohort study, we recruited women with IBD treated with UST during pregnancy between 2019 and 2021. Outcomes were compared among patients treated with UST, anti-tumour necrosis factor α, (anti-TNF) and non-UST, non-anti-TNF therapies. UST-treated patients were matched 1:2 to controls according to age, body mass index and parity. Newborns were followed up to 12 months.

RESULTS

We recruited 129 pregnant patients: UST 27; anti-TNF 52; non-UST, non-anti-TNF 50 (thiopurine or mesalazine 30, no therapy 20); Crohn's disease 25 (96.9%). Overall, pregnancy, neonatal and newborn outcomes were satisfactory, with no significant differences among patients treated with UST, anti-TNF and non-UST non-anti-TNF agents for obstetrical maternal complications [UST 3 (11.5%), anti TNF 12 (23.1%), non UST, non-anti-TNF 4 (8.2%), p = 0.095], pre-term delivery [1 (4.3%), 9 (18.4%), 4 (5.7%), p = 0.133], low birth weight [1 (4.2%), 5 (10.2%), 4 (8.3%), p = 0.679], or first year newborn hospitalisation [2 (9.1%), 4 (8.2%), 3 (6.1%), p = 0.885].

CONCLUSION

Pregnant patients with IBD treated with UST demonstrated favourable pregnancy and neonatal outcomes that were comparable with those in patients treated with anti-TNF or other therapy. Data are reassuring for patients with IBD and their physicians when considering UST during pregnancy.

Для цитирования: Avni-Biron Irit, Mishael Tali, Zittan Eran, Livne-Margolin Moran, Zinger Adar, Tzadok Roie, Goldenberg Rosie, Kopylov Uri, Ron Yulia, Hadar Eran, Helman Sarit, Granovsky Sorina Grisaru, Ollech Jacob E, Arazi Ayelet, Farkash Rivka, Pauker Maor H, Yanai Henit, Dotan Iris, Shitrit Ariella Bar-Gil. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.. Alimentary pharmacology & therapeutics. 2022. DOI: 10.1111/apt.17224.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.